Mixed results for AstraZeneca in Scotland while patient access scheme swings yes for Pfizer
This article was originally published in Scrip
Executive Summary
There was mixed news for AstraZeneca in Scotland after the country's health technology appraisal body, the Scottish Medicines Consortium, turned down Seroquel (quetiapine) for major depressive episodes in bipolar disorder but accepted Brillique (ticagrelor)for atherothrombotic events in adult with acute coronary syndromes. Meanwhile, a patient access scheme helped Pfizer secure a yes for its Sutent (sunitinib).